Bevra Hannahs Hahn

Bevra Hannahs Hahn's AcademicInfluence.com Rankings

Bevra Hannahs Hahn

Philosophy

#7474

World Rank

#10695

Historical Rank

Logic

#4517

World Rank

#5826

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Bevra Hannahs Hahn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bevra Hannahs Hahn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis (2012) (1149)
Combined Oral Contraceptives in Women With Systemic Lupus Erythematosus (2005) (958)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (2019) (936)
Dubois' Lupus Erythematosus (1987) (637)
The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial (2005) (577)
Antibodies to DNA. (1998) (439)
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (2019) (419)
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. (2006) (395)
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. (2006) (390)
A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. (1982) (380)
Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. (1979) (374)
Human polymorphism at microRNAs and microRNA target sites. (2013) (330)
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. (1982) (319)
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. (1997) (287)
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. (1999) (279)
Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. (1985) (269)
The role of miRNA in inflammation and autoimmunity. (2013) (268)
Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus. Comparison of antibodies in serum and renal eluates. (1980) (255)
Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus (2010) (229)
The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. (2007) (226)
Accelerated atherosclerosis in patients with SLE—mechanisms and management (2012) (212)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study (2018) (204)
Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility (2011) (193)
Cutting Edge: Regulatory T Cells Directly Suppress B Cells in Systemic Lupus Erythematosus1 (2009) (189)
Th17 cells in inflammation and autoimmunity. (2014) (187)
Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. (1981) (184)
Belimumab for systemic lupus erythematosus. (2013) (177)
Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. (2011) (177)
Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity (1996) (175)
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. (2009) (162)
Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. (1988) (160)
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. (2005) (159)
Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. (1984) (157)
Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. (1994) (150)
International consensus for a definition of disease flare in lupus (2011) (149)
T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus (1995) (149)
Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. (1984) (148)
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids (2011) (141)
Tolerogenic Treatment of Lupus Mice with Consensus Peptide Induces Foxp3-Expressing, Apoptosis-Resistant, TGFβ-Secreting CD8+ T Cell Suppressors1 (2005) (140)
Systemic lupus erythematosus and accelerated atherosclerosis. (2003) (136)
Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. (1987) (136)
Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. (1992) (134)
Human Double-Negative T Cells in Systemic Lupus Erythematosus Provide Help for IgG and Are Restricted by CD1c1 (2000) (125)
Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. (1990) (123)
CD8+ Tregs in lupus, autoimmunity, and beyond. (2010) (118)
Ig-Reactive CD4+CD25+ T Cells from Tolerized (New Zealand Black × New Zealand White)F1 Mice Suppress In Vitro Production of Antibodies to DNA1 (2004) (118)
PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. (1999) (117)
Association of a functional IRF7 variant with systemic lupus erythematosus. (2011) (116)
Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. (2001) (115)
A missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases (2017) (112)
Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. (1995) (112)
A Panel of Biomarkers Is Associated With Increased Risk of the Presence and Progression of Atherosclerosis in Women With Systemic Lupus Erythematosus (2014) (110)
Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis (2008) (110)
Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus. (1990) (108)
Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. (1979) (105)
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. (2007) (102)
MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus (2013) (99)
Characterization of IgG monoclonal anti‐cardiolipin/anti‐β2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies (1999) (97)
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups (2012) (95)
Abnormal distribution of Fc gamma receptor type IIa polymorphisms in Korean patients with systemic lupus erythematosus. (1998) (95)
Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA. Possible role of anti-idiotypic antibodies. (1983) (94)
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention (2011) (94)
Identification of Anti-Thrombin Antibodies in the Antiphospholipid Syndrome That Interfere with the Inactivation of Thrombin by Antithrombin1 (2001) (93)
Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy. (1976) (90)
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. (2005) (90)
Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. (1995) (90)
Identification of Anti-Plasmin Antibodies in the Antiphospholipid Syndrome That Inhibit Degradation of Fibrin1 (2004) (85)
PD-1, gender, and autoimmunity. (2010) (80)
Induction of Autoantibody Production Is Limited in Nonautoimmune Mice1 (2002) (80)
Systemic lupus erythematosus genome scan: support for linkage at 1q23, 2q33, 16q12-13, and 17q21-23 and novel evidence at 3p24, 10q23-24, 13q32, and 18q22-23. (2004) (79)
Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. (2006) (79)
Low physical activity is associated with proinflammatory high‐density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus (2010) (78)
CD8+ T Cell-Mediated Suppression of Autoimmunity in a Murine Lupus Model of Peptide-Induced Immune Tolerance Depends on Foxp3 Expression1 (2007) (77)
A peptide derived from an autoantibody can stimulate T cells in the (NZB x NZW)F1 mouse model of systemic lupus erythematosus. (1993) (75)
Key autoantigens in SLE. (2005) (75)
Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus (2007) (75)
Idiotypic characteristics of immunoglobulins associated with systemic lupus erythematosus. Studies of antibodies deposited in glomeruli of humans. (1989) (74)
Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. (2003) (73)
Management of systemic lupus erythematosus. (1982) (68)
Lupus autoantibodies to native DNA cross-react with the A and D SnRNP polypeptides. (1994) (68)
Idiotype restriction in murine lupus; high frequency of three public idiotypes on serum IgG in nephritic NZB/NZW F1 mice. (1987) (67)
Can Women with Systemic Lupus Erythematosus Safely Use Exogenous Estrogens? (1995) (66)
Dubois' Lupus Erythematosus and Related Syndromes (2018) (65)
Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. (1998) (65)
"Rheumatoid" nodules in systemic lupus erythematosus. (1970) (64)
Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. (2007) (64)
pConsensus Peptide Induces Tolerogenic CD8+ T Cells in Lupus-Prone (NZB × NZW)F1 Mice by Differentially Regulating Foxp3 and PD1 Molecules1 (2008) (62)
Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. (2008) (61)
Reciprocal T‐B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis (1998) (61)
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus. (2002) (58)
Blockade of Programmed Death-1 in Young (New Zealand Black × New Zealand White)F1 Mice Promotes the Suppressive Capacity of CD4+ Regulatory T Cells Protecting from Lupus-like Disease (2013) (55)
Familiality and co-occurrence of clinical features of systemic lupus erythematosus. (2002) (54)
Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. (2015) (50)
Production of monoclonal murine antibodies to DNA by somatic cell hybrids. (1980) (50)
Detection of native and denatured DNA antibody forming cells by the enzyme-linked immunospot assay. A clinical study of (New Zealand black x New Zealand white)F1 mice. (1986) (49)
A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. (2003) (49)
Characteristics of pathogenic subpopulations of antibodies to DNA. (1982) (48)
An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. (1999) (48)
Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. (2005) (48)
Laquinimod Delays and Suppresses Nephritis in Lupus‐Prone Mice and Affects Both Myeloid and Lymphoid Immune Cells (2014) (46)
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria (2018) (44)
Cellular and Molecular Mechanisms of Regulation of Autoantibody Production in Lupus (2005) (44)
Allogeneic MHC antigen requirements for lupus-like autoantibody production and nephritis in murine graft-vs-host disease. (1988) (44)
Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression (2013) (44)
Pathogenic subsets of antibodies to DNA. (1989) (43)
Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. (2004) (42)
Maternal HLA class II compatibility in men with systemic lupus erythematosus. (2005) (42)
Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus (2013) (41)
A public idiotypic determinant is present on spontaneous cationic IgG antibodies to DNA from mice of unrelated lupus-prone strains. (1984) (41)
Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. (2011) (40)
Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance. (2012) (40)
Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. (2003) (40)
Intravenous Injection of a D1 Protein of the Smith Proteins Postpones Murine Lupus and Induces Type 1 Regulatory T Cells1 (2004) (39)
Blockade of Programmed Death-1 in Young (New Zealand Black × New Zealand White)F1 Mice Promotes the Activity of Suppressive CD8+ T Cells That Protect from Lupus-Like Disease (2010) (39)
Differences between CD8+ T cells in lupus‐prone (NZB × NZW) F1 mice and healthy (BALB/c × NZW) F1 mice may influence autoimmunity in the lupus model (2004) (36)
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus (2020) (35)
Genes, tolerance and systemic autoimmunity. (2012) (35)
Cutaneous vasculitis in breast cancer treated with chemotherapy. (2008) (35)
Antibodies against the Activated Coagulation Factor X (FXa) in the Antiphospholipid Syndrome That Interfere with the FXa Inactivation by Antithrombin1 (2006) (34)
Major histocompatibility complex associations with systemic lupus erythematosus. (1988) (33)
Targeted therapies in systemic lupus erythematosus: successes, failures and future (2011) (33)
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020) (32)
Impact of Changes in Medicare Home Health Care Reimbursement on Month-to-Month Home Health Utilization Between 1996 and 2001 for a National Sample of Patients Undergoing Orthopedic Procedures (2006) (31)
Impact of the Medicare Short Stay Transfer Policy on patients undergoing major orthopedic surgery. (2007) (31)
Novel Autoantibodies against the Activated Coagulation Factor IX (FIXa) in the Antiphospholipid Syndrome That Interpose the FIXa Regulation by Antithrombin1 (2009) (30)
Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. (2010) (29)
The Complexity of Care for Patients with Rheumatoid Arthritis: Metrics for Better Understanding Chronic Disease Care (2007) (29)
Manipulation of immune regulation in systemic lupus erythematosus. (2005) (29)
Diversity of Ig V gene segments found in anti-DNA autoantibodies from a single (NZB x NZW)F1 mouse. (1989) (29)
Antibody-nucleic acid complexes. Conformational and base specificities associated with spontaneously occurring poly- and monoclonal anti-DNA antibodies from autoimmune mice. (1984) (28)
Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice. (2008) (26)
Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. (2007) (26)
Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. (2007) (25)
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021) (25)
Gene Vaccination for the Induction of Immune Tolerance (2007) (25)
Magnetic resonance imaging identifies early femoral head ischemic necrosis in patients receiving systemic glucocorticoid therapy. (1989) (23)
Pathogenesis of Systemic Lupus Erythematosus (2009) (21)
Chapter 17 – Animal Models of SLE (2013) (21)
Systemic lupus erythematosus. (1995) (21)
Lessons in lupus: the mighty mouse (2001) (21)
Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration (2004) (21)
Idiotypic spreading promotes the production of pathogenic autoantibodies. (1988) (19)
Maintenance of efficacy and safety of ustekinumab through 1 year in a randomized phase II trial of patients with active systemic lupus erythematosus. (2019) (17)
Influenza Vaccination in Patients With Rheumatic Diseases (2017) (16)
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. (2003) (16)
Leptin-based immune intervention: current status and future directions. (2003) (16)
Fcγ receptor IIIA polymorphism in Korean patients with systemic lupus erythematosus (2002) (16)
Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis? (2010) (16)
Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. (2006) (15)
Systemic lupus erythematosus: modern strategies for management: a moving target. (2007) (15)
Modulation of p38 MAPK Activity in Regulatory T Cells after Tolerance with Anti-DNA Ig Peptide in (NZB × NZW)F1 Lupus Mice1 (2009) (15)
Rapid development of constrictive pericarditis in a patient with systemic lupus erythematosus. (1973) (15)
Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus (2003) (14)
Osteoporosis: diagnosis and management. (1988) (14)
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production (2016) (14)
Interferon-inducible gene 202b controls CD8+ T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB × NZW) F1 lupus mice (2011) (14)
Development and evaluation of a patient self-report case-finding method for rheumatoid arthritis. (2004) (13)
Antibody-nucleic acid complexes. Identification of antigenic determinant of a murine monoclonal antibody specific for single-stranded nucleic acids. (1982) (13)
Tolerance induced by anti-DNA Ig peptide in (NZB×NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. (2012) (13)
Gene-Marked Autologous Hematopoietic Stem Cell Transplantation of Autoimmune Disease (2004) (13)
Production of anti-erythrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. (1996) (13)
Case finding for population-based studies of rheumatoid arthritis: comparison of patient self-reported ACR criteria-based algorithms to physician-implicit review for diagnosis of rheumatoid arthritis. (2004) (12)
Distinct gene signature revealed in white blood cells, CD4+ and CD8+ T cells in (NZBx NZW) F1 lupus mice after tolerization with anti-DNA Ig peptide (2010) (12)
Self Ig peptides that help anti-DNA antibody production: importance of charged residues (1998) (12)
Tuning immune suppression in systemic autoimmunity with self-derived peptides. (2008) (11)
A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus (2021) (11)
Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. (2015) (10)
Interferon Genes Are Influenced by 17β-Estradiol in SLE (2021) (10)
Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE (2019) (10)
Idiotypic characteristics of immunoglobulins associated with human systemic lupus erythematosus. Association of high serum levels of IdGN2 with nephritis but not with HLA class II genes predisposing to nephritis. (1990) (10)
Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels. (2020) (9)
New therapies in SLE. (2008) (9)
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study (2021) (9)
Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus. (2009) (8)
Identification and Contribution of Inflammation-Induced Novel MicroRNA in the Pathogenesis of Systemic Lupus Erythematosus (2022) (8)
Characteristics of T cells that participate in the pathogenesis of SLE (1997) (8)
The genetic basis of systemic lupus erythematosus. (1998) (8)
Fcgamma receptor IIIA polymorphism in Korean patients with systemic lupus erythematosus. (2002) (8)
Leptin in non-autoimmune inflammation. (2009) (8)
T cell up-regulation of B cells via their idiotypes contributing to the development of systemic lupus erythematosus. A hypothesis. (1988) (7)
Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design (2017) (7)
Gouty tophi in a pancreatic pseudocyst. (2002) (7)
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus (2022) (7)
Sex hormones and gender influence the expression of Foxp3 and regulatory T cells in SLE patients (2011) (6)
Peptides from Vh regions of antibodies to DNA activate T cell help to upregulate autoantibody synthesis. (1997) (6)
Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus (2021) (6)
Studies of tolerance to DNA in NZB/NZW F1 mice. (1977) (6)
The role of VH determinants in systemic lupus erythematosus (2002) (6)
Preclinical studies with synthetic peptides in systemic lupus erythematosus. (2012) (6)
Polyarteritis nodosa of the epididymis in a patient with Whipple's disease. (1987) (5)
Glucocorticoid-induced osteoporosis. (1995) (5)
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus (2022) (5)
Update – systemic lupus erythematosus (2007) (5)
Chapter 3 – The Pathogenesis of SLE (2013) (4)
S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study (2018) (4)
A pathophysiologic approach to the clinical management of arthritis and pain: current and future implications. (2004) (4)
Idiotype regulatory networks promote autoantibody formation. (1987) (4)
OP0041 MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY (2019) (4)
Treatment of Autoimmune Disease: Established Therapies (2020) (3)
Association of PPP2CA polymorphisms with SLE susceptibility in multiple ethnic groups (2011) (3)
Somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide protects (NZB_NZW)F1 lupus-prone mice from renal disease. (2007) (3)
Effects of Peptide-Induced Immune Tolerance on Murine Lupus (2021) (3)
Ig-transgenic mice as models for studying the regulation and role of anti-DNA antibodies in murine lupus (1992) (3)
On the edge of the millennium: prospects and problems for our patients and us. (2000) (3)
Antibody-nucleic acid complexes. Antigenic domains within nucleosides as defined by solid-phase immunoassay. (1984) (3)
Contribution of major histocompatibility complex (MHC) to upregulation of anti-DNA antibody in transgenic mice. (1993) (3)
Analyses of serum levels of type 1, type 2 and type 3 cytokines reveal multiple abnormalities in lupus‐prone (NZB × NZW) F1 mice (2004) (3)
Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss (2007) (2)
Cellular and Molecular Phenotypes of pConsensus Peptide (pCons) Induced CD8+ and CD4+ Regulatory T Cells in Lupus (2021) (2)
Methods for reducing undesirable side effects of glucocorticoids. (1984) (2)
Lithium heparin crystals simulating CPPD crystals (1976) (2)
ADPRT ALLELES FROM THE CHROMOSOME 1q41-q42 LINKED REGION ARE ASSOCIATED WITH SLE (1998) (2)
The characterization of DNA antibody idiotypes—A discussion (1990) (2)
OP0278 BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (2)
OP0161 ASSOCIATION OF BASELINE CYTOTOXIC GENE EXPRESSION WITH USTEKINUMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (2)
Improving joint disease in patients with rheumatoid arthritis: is this enough to treat the accompanying dyslipidemias? (2002) (2)
Interferon Genes are Influenced by Sex Hormones (17b-estradiol) in SLE (2020) (2)
Suppression of autoimmune diseases with anti-idiotypic antibodies: Murine lupus nephritis as a model (2005) (2)
TYPE II BUT NOT TYPE I INTERFERON SIGNIFIES CLINICAL RESPONSE TO USTEKINUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (2)
251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus (2019) (2)
Sex hormones and gender influence the function of regulatory T cells in SLE patients. (2010) (2)
Induction of Autoantibody Production Is Limited in Nonautoimmune Mice1 (2002) (1)
GG-04 A missense mutation in neutrophil cytosolic factor 1 (NCF1) is associated with susceptibility to multiple autoimmune diseases (2016) (1)
08 IL-12/23 directed therapies in SLE (2020) (1)
Idiotypes, Antibodies and Immunopathology (1992) (1)
Idiotype selection is an immunoregulatory mechanism which contributes to the pathogenesis of systemic lupus erythematosus (1988) (1)
A pathophysiologic approach to the clinical management of arthritis and pain: current and future implications. (2004) (1)
CD8+ T Regulatory Cells in Lupus (2021) (1)
Overview of Lupus Pathogenesis (2019) (1)
Georgia Abortion Law and Our Commitment to Patients (2020) (1)
Somatic B-Cell Gene Vaccination with Anti-DNA Ig Consensus Peptide Protects (NZB × NZW) F1 Lupus Mice From Renal Disease (2007) (1)
Letter: Lithium heparin crystals simulating CPPD crystals. (1976) (1)
THU0271 PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES (2020) (1)
Erratum: Induction of autoantibody production is limited in nonautoimmune mice (Journal of Immunology (2002) 169 (587-594)) (2002) (1)
Can Physical Signs or Magnetic Resonance Imaging Substitute for Diagnostic Arthroscopy in Knee Osteoarthritis Patients with Suspected Internal Derangements? A Pilot Study (2000) (1)
T.113. Leptin Worsens Hyperlipidemia and Atherosclerosis Induced by High Fat Diet in (NZB × NZW)F1 Lupus-Prone Mice (2009) (1)
Pregnancy in Women With Systemic Lupus Erythematosus: Messages for the Clinician (2015) (1)
Lawrence E. Shulman, MD, PhD, 1919–2009 (2010) (1)
PD 1 Molecules Mice by Differentially Regulating Foxp 3 and 1 T Cells in Lupus-Prone ( NZB × NZW ) F + pConsensus Peptide Induces Tolerogenic CD 8 (2008) (1)
Altered PD-1-PD-L1 Pathway in CD8+ T cells of (New Zealand Black x New Zealand White) BWF1 Mice with Anti-PD-1 antibody (99.29) (2009) (0)
The 1978 annual meeting of the American Rheumatism Association. (1978) (0)
FRI0303 Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study (2018) (0)
List of Contributors (2019) (0)
Role of CD8+ Ti cells in Suppression of Autoimmunity Depends on Foxp3 Expression (2007) (0)
Reply: To PMID 22556106. (2013) (0)
Sex hormones and gender influence the function of regulatory T cells in SLE patients. (143.54) (2010) (0)
List of Contributors (2020) (0)
Sa.37. Defective CD4+ Regulatory T Cells and CD8+ Suppressor T Cells in SLE Patients: Quantitative and Functional Gender-biased Differences (2008) (0)
THU0303 Longitudinal Patterns in SLE Response To Standard of Care Therapy: Implications for SLE Clinical Trial Design (2016) (0)
POS0183 THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS (2022) (0)
Reply to Choubey et al. (2011) (0)
Regulation of autoantibody production by multiple mechanisms in immune tolerance (2004) (0)
Autoantibodies as a Source of Peptides That Regulate Autoantibody Production (1999) (0)
Contribution of novel microRNAs in the pathogenesis of rheumatoid arthritis (P4078) (2013) (0)
PREDICTION OF FETAL LOSS IN PREGNANT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (0)
Some antiphospholipid antibodies recognize conformational epitopes shared by β 2 GPI and the homologous catalytic domains of several serine proteases (2007) (0)
Lupus Mice 1 Anti-DNA Ig Peptide in ( NZB × NZW ) F Regulatory T Cells after Tolerance with Modulation of p 38 MAPK Activity in (2009) (0)
Induces Type 1 Regulatory T Cells Smith Proteins Postpones Murine Lupus and Intravenous Injection of a D1 Protein of the (2004) (0)
Oral administration of the tolerogenic peptide pCons induces CD4+CD25+Foxp3+ regulatory T cells in mesenteric lymph nodes (99.28) (2009) (0)
Localization of radiolabeled anti-DNA monoclonal antibodies in murine systemic lupus erythematosus (SLE) (1984) (0)
Dna antibodies from mice of unrelated strains bear similar idiotypes. Abstr. (1983) (0)
195 Sequential blockade of OX40L followed by PD-1 altered the suppressive function and proliferation of CD4+ regulatory T cells in lupus mice (2019) (0)
Expression of Interferon-inducible Genes is Influenced by Sex Hormones in SLE (2016) (0)
Chapter 77 – Systemic Lupus Erythematosus (2013) (0)
Sa.51. Natural Treg Cells Modulate Murine Lupus by Directly Suppressing Autoantibody-producing B Cells (2008) (0)
28 Clinical science highlights that are transforming treatment (2021) (0)
Can Drug Effects Help Elucidate the Pathogenesis of SLE (2006) (0)
Antithrombin Interfere with the Inactivation of Thrombin the Antiphospholipid Syndrome That Identification of AntiThrombin Antibodies in (2001) (0)
Reply to Choubey et al. (2011) (0)
Foxp 3 Expression Peptide-Induced Immune Tolerance Depends Autoimmunity in a Murine Lupus Model of T Cell-Mediated Suppression of + CD 8 (2007) (0)
Sa.38. NF-κB-Regulated Genes Control Antiapoptotic Genes and Pathways in Tolerized CD8+ Inhibitory T Cells Isolated from SLE-Prone Mice (2008) (0)
Antibodies to DNA Epiphenomena or Pathogens (1985) (0)
Treg Cells Directly Suppress Anti-DNA Ig-producing B Cells Through TGFβ-mediated Mechanisms in Murine Lupus (2007) (0)
Inactivation by Antithrombin Syndrome That Interfere with the FXa Factor X (FXa) in the Antiphospholipid Antibodies against the Activated Coagulation (2006) (0)
ErythematosusSuppress B Cells in Systemic Lupus Cutting Edge: Regulatory T Cells Directly (2009) (0)
Lupus nephritis: therapeutic decisions. (1990) (0)
201 Ustekinumab targets a novel mechanism of action to treat patients with systemic lupus erythematosus (2019) (0)
GENE VACCINATION WITH ANTI-DNA ANTIBODY CONSENSUS PEPTIDE PREVENTS LUPUS ONSET IN LUPUS-PRONE MICE THROUGH ACTIVATION OF CD8–CD28– TREG (2008) (0)
Reply (2012) (0)
Sex hormones and gender influence the expression of Foxp3 and regulatory T cells in SLE patients (115.18) (2011) (0)
Bone loss in patients receiving alternate day or daily glucocorticoid therapy (1980) (0)
Tolerization of BWF1 lupus mice with pConsensus peptide results in a distinct gene signature in WBC, CD4+ and CD8+T cells: Role of Foxp3 and IFI202b in suppression of SLE (50.22) (2009) (0)
Laquinimod suppression of lupus nephritis in BWF1 mice associates in renal tissue with increase of myeloid suppressor cells and switch of macrophages to anti-inflammatory type II (P5193) (2013) (0)
T.16.5. Natural T Reg Cells Directly Suppress B Cells in Systemic Lupus Erythematosus (2009) (0)
Blockade of Programmed death-1 induces functional CD4+ regulatory T cells to resist apoptosis in (New Zealand Black x New Zealand White)F1 lupus-prone mice (115.25) (2011) (0)
CD8+ T Cell- mediated Suppression of Autoimmunity in a Murine Lupus Model of Peptide-Induced Immune Tolerance Depends on Foxp3 Expression (130.19) (2007) (0)
Autoimmunity and tolerance in Ig-transgenic mice: murine SLE as a model to study B cell tolerance. (1994) (0)
Preface (2019) (0)
Expression of interferon-inducible genes is influenced by sex hormones and gender in SLE (P1380) (2013) (0)
T Cell Suppressors + -Secreting CD8 b -Expressing, Apoptosis-Resistant, TGF Foxp3 Consensus Peptide Induces Tolerogenic Treatment of Lupus Mice with (2005) (0)
Teaching effectiveness of videotapes on arthritis for medical students (1980) (0)
CT-05 Longitudinal patterns in SLE response to standard of care therapy: implications for clinical trial design (2016) (0)
Reply (2013) (0)
Common MHC-binding determinants are shared by murine antibodies to DNA derived from different V-H genes (1993) (0)
Animal Models in Lupus (2019) (0)
Leptin Modulates Treg Cell Activity in Human SLE (2007) (0)
902 Loss-of-function variants inSAT1cause X-linked Childhood-onset Systemic Lupus Erythematosus (2022) (0)
Sa.49. Anti-DNA Ig Peptides Promote Regulatory T Cell Activity in SLE Patients (2008) (0)
Anti-apoptotic Genes are Upregulated in Tolerized CD8+ Regulatory T Cells Isolated from SLE-Prone Mice (99.41) (2009) (0)
Limited in Nonautoimmune Mice Induction of Autoantibody Production Is (2017) (0)
T.17.5. Critical Role of p38 MAPK in the Activity of Adaptive Regulatory T Cells Induced by Anti-DNA Ig Peptide in (NZB × NZW)F1 Lupus Mice (2009) (0)
Sa.28. Protective Effects of Polyclonal Foxp3+CD4+CD25+ Cells Induced Ex-Vivo on SLE Mouse Models (2008) (0)
Unmet needs: therapeutic standards of care (2013) (0)
OR.28. Mechanisms of Autoimmune Modulation Induced By Leptin in Murine Systemic Lupus Erythematosus (2006) (0)
F.57. Identification of Genes in Non-T Effector Cells Influencing Immune Tolerance in Murine SLE (2006) (0)
Degradation of Fibrin the Antiphospholipid Syndrome That Inhibit Identification of Anti-Plasmin Antibodies in Hahn and (2004) (0)
the FIXa Regulation by Antithrombin Antiphospholipid Syndrome That Interpose Coagulation Factor IX (FIXa) in the Novel Autoantibodies against the Activated (2009) (0)
Patient Guide to Lupus Erythematosus (2013) (0)
Sa.10. B Cells are a Target of Suppression by Peripheral CD8 T Cells from Tolerized NZB/NZW (F1) Lupus Mice (2008) (0)
Bcl2, PDGFRβ and M-CSF are upregulated in monocytes from SLE patients with defective HDL and atherosclerosis (99.42) (2009) (0)
Role of IFI202b in the suppressive ability of CD8+Treg induced in (NZB x NZW) F1 lupus mice (143.56) (2010) (0)
AB0512 Use of Nominal Group Technique To Facilitate Item Reduction for Sle Classification Criteria Development (2016) (0)
O9 Reduction of interferon-γ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE (2020) (0)
Bcl2, PDGFR{beta} and M-CSF are upregulated in monocytes from SLE patients with defective HDL and atherosclerosis (2009) (0)
Novel microRNAs in the pathogenesis of rheumatoid arthritis (2017) (0)
Proceedings of the Second Update on Psoriatic Disease, University Federico II Congress Center, July 6–7, 2011, Naples, Italy. (2012) (0)
Sa.53. Leptin Effects on Regulatory T Cells in SLE (2008) (0)
OR.8. Role of Sex Hormones and Gender in the Functional Differences of Regulatory and CD8+Suppressor T Cells in SLE Patients (2009) (0)
RENAL AND NONRENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: MEETING THE CLINICAL CHALLENGE (2008) (0)
Treatment of SLE: Bridging the Gap from Clinical Trials to Practice (2013) (0)
Expression of Interferon Genes is Influenced by Sex Hormones in SLE (2019) (0)
AB0850 CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA & SEVERITY INDEX (CLASI) DEMONSTRATES THRESHOLDS FOR DETECTION OF TREATMENT RESPONSE IN A PHASE 2, PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB IN SLE (2020) (0)
Clinical conference: lupus erythematosus. (1975) (0)
Association Of ACommon Haplotype Of Complement Receptor 2(CR2) With Increased Risk Of SLE (2007) (0)
Women in rheumatology. The event at the American College of Rheumatology Annual Scientific Meeting in October 1992. (1993) (0)
Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus (2022) (0)
Sex hormones and gender influence the expression and function of regulatory T cells differentially in SLE patients (2018) (0)
Risk factors for steroid-induced bone loss (1980) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bevra Hannahs Hahn?

Bevra Hannahs Hahn is affiliated with the following schools:

University of California, Los Angeles

Bevra Hannahs Hahn's Academic­Influence.com Rankings

Why Is Bevra Hannahs Hahn Influential?

Bevra Hannahs Hahn's Published Works

Published Works

What Schools Are Affiliated With Bevra Hannahs Hahn?

Bevra Hannahs Hahn's AcademicInfluence.com Rankings